Literature DB >> 2292232

The practical use of methotrexate in psoriasis.

J P Tung1, H I Maibach.   

Abstract

Psoriasis is an inflammatory disease of the skin associated with increased epidermal proliferation. The aetiology of the disease is unknown, but there seems to be a genetic predisposition. The goal of therapy in the treatment of psoriasis is to decrease the rate of epidermal proliferation and the underlying inflammation. Topical application of steroids and coal tar are the therapies of choice; however, for those patients with severe recalcitrant psoriasis who have failed conventional topical therapy methotrexate is an established alternative. The use of methotrexate in psoriasis is limited by its toxicity, and proper patient selection and close monitoring are essential in achieving good clinical response. The dosage used should be the lowest that will maintain the patient in comfort, not necessarily that which produces total resolution. Caution should be exercised when other agents are used concurrently with methotrexate, and possible drug interactions should be identified as these may influence the effectiveness and toxicity of methotrexate therapy. The common side effects associated with the use of methotrexate in psoriasis include bone marrow suppression, gastrointestinal symptoms and hepatotoxicity. Liver damage is a major concern in long term methotrexate therapy and thus liver biopsies are warranted to monitor any pathological changes. The drug is a known teratogen and should be avoided in pregnant patients. Women of childbearing age should use reliable contraception during therapy. Patients should be made aware of the signs and symptoms of methotrexate toxicity and inform their physicians promptly as most adverse effects can be ameliorated with appropriate dosage adjustment. Methotrexate will continue to play a major role in the treatment of psoriasis and it is thus important that it be used safely.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2292232     DOI: 10.2165/00003495-199040050-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  90 in total

1.  Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics.

Authors:  A Nyfors
Journal:  Acta Pathol Microbiol Scand A       Date:  1977-07

2.  Pulmonary function in patients on long-term, low-dose methotrexate.

Authors:  T J Phillips; P J Wallis; D H Jones; H Baker
Journal:  Br J Dermatol       Date:  1986-12       Impact factor: 9.302

3.  Absorption and local action of methotrexate in human and mouse skin.

Authors:  W D Stewart; S M Wallace; J O Runikis
Journal:  Arch Dermatol       Date:  1972-09

4.  Hepatotoxicity of prolonged methotrexate therapy for rheumatoid arthritis.

Authors:  A H Mackenzie
Journal:  Cleve Clin Q       Date:  1985

5.  Aminopterin and methotrexate: folic acid deficiency.

Authors:  J Warkany
Journal:  Teratology       Date:  1978-06

6.  Methotrexate therapy in rheumatoid arthritis: 15 years experience.

Authors:  R T Hoffmeister
Journal:  Am J Med       Date:  1983-12-30       Impact factor: 4.965

7.  Psoriasis, methotrexate, and oligospermia.

Authors:  A Sussman; J M Leonard
Journal:  Arch Dermatol       Date:  1980-02

8.  Hepatotoxicity after long-term methotrexate therapy.

Authors:  F S Reynolds; W M Lee
Journal:  South Med J       Date:  1986-05       Impact factor: 0.954

9.  Dose dependent methotrexate elimination following bolus intravenous injection.

Authors:  J R Lawrence; W H Steele; J F Stuart; C A McNeill; J G McVie; B Whiting
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

10.  Topical treatment of psoriatic skin with methotrexate cream: a clinical, pharmacokinetic, and histological study.

Authors:  P Bjerring; H I Beck; H Zachariae; H Søgaard
Journal:  Acta Derm Venereol       Date:  1986       Impact factor: 4.437

View more
  4 in total

Review 1.  Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options.

Authors:  Gil Yosipovitch; Mark B Y Tang
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

2.  Better effect of methotrexate on C-reactive protein during daily compared to weekly treatment in rheumatoid arthritis.

Authors:  P Seideman
Journal:  Clin Rheumatol       Date:  1993-06       Impact factor: 2.980

3.  Microneedle and iontophoresis mediated delivery of methotrexate into and across healthy and psoriatic skin.

Authors:  Deepal Vora; Harsha T Garimella; Carrie L German; Ajay K Banga
Journal:  Int J Pharm       Date:  2022-03-21       Impact factor: 6.510

4.  Methotrexate showed efficacy both in Crohn's disease and ulcerative colitis, predictors of surgery were identified in patients initially treated with methotrexate monotherapy.

Authors:  Mengyao Wang; Jingwen Zhao; Heran Wang; Changqing Zheng; Bing Chang; Lixuan Sang
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.